Work Description
Title: Pharmacometabolomics of L-carnitine-Kaplan-Meier survival data: numbers at risk Open Access Deposited
Attribute | Value |
---|---|
Methodology |
|
Description |
|
Creator | |
Depositor |
|
Contact information | |
Discipline | |
Funding agency |
|
ORSP grant number |
|
Keyword | |
Citations to related material |
|
Resource type | |
Last modified |
|
Published |
|
Language | |
DOI |
|
License |
To Cite this Work:
(2021). Pharmacometabolomics of L-carnitine-Kaplan-Meier survival data: numbers at risk [Data set], University of Michigan - Deep Blue Data. https://doi.org/10.7302/vvqp-ma61
(2021). Pharmacometabolomics of L-carnitine-Kaplan-Meier survival data: numbers at risk [Data set], University of Michigan - Deep Blue Data. https://doi.org/10.7302/vvqp-ma61
Relationships
- This work is not a member of any user collections.
Files (Count: 17; Size: 784 KB)
Thumbnailthumbnail-column | Title | Original Upload | Last Modified | File Size | Access | Actions |
---|---|---|---|---|---|---|
|
READ_ME.txt | 2021-02-03 | 2021-02-05 | 4.1 KB | Open Access |
|
![]() |
SA-at_risk_L-carnitine_18g_v_PL_...s.csv | 2021-02-05 | 2021-02-05 | 599 Bytes | Open Access |
|
![]() |
SA-at_risk_35uM_L-carnitine_18g_...e.csv | 2021-02-05 | 2021-02-05 | 261 Bytes | Open Access |
|
![]() |
SA-at_risk_30uM_L-carnitine_18g_...e.csv | 2021-02-05 | 2021-02-05 | 284 Bytes | Open Access |
|
![]() |
SA-at_risk_21uM_L-carnitine_18g_...e.csv | 2021-02-05 | 2021-02-05 | 380 Bytes | Open Access |
|
![]() |
SA-at_risk_L-carnitine_18g_v_PL_...s.csv | 2021-02-05 | 2021-02-05 | 585 Bytes | Open Access |
|
![]() |
SA-at_risk_88uM_L-carnitine_18g_...e.csv | 2021-02-05 | 2021-02-05 | 384 Bytes | Open Access |
|
![]() |
SA-at_risk_75uM_L-carnitine_18g_...e.csv | 2021-02-05 | 2021-02-05 | 477 Bytes | Open Access |
|
![]() |
SA-at_risk_60uM_L-carnitine_18g_...e.csv | 2021-02-05 | 2021-02-05 | 535 Bytes | Open Access |
|
|
SA-acylcarnitines-all_subjects.pdf | 2021-02-05 | 2021-02-05 | 100 KB | Open Access |
|
|
SA-acetylcarnitine-21uM.pdf | 2021-02-05 | 2021-02-05 | 96.2 KB | Open Access |
|
|
SA-acetylcarnitine-30uM.pdf | 2021-02-05 | 2021-02-05 | 95.3 KB | Open Access |
|
|
SA-acetylcarnitine-35uM.pdf | 2021-02-05 | 2021-02-05 | 90.4 KB | Open Access |
|
|
SA-NMR_data-all_subjects.pdf | 2021-02-05 | 2021-02-05 | 102 KB | Open Access |
|
|
SA-NMR_data-valine-60uM.pdf | 2021-02-05 | 2021-02-05 | 101 KB | Open Access |
|
|
SA-NMR_data-valine-75uM.pdf | 2021-02-05 | 2021-02-05 | 95.9 KB | Open Access |
|
|
SA-NMR_data-valine-88uM.pdf | 2021-02-05 | 2021-02-05 | 95.7 KB | Open Access |
|
"Survival analyses conducted in an ancillary study of the RACE trial (https://clinicaltrials.gov/ct2/show/NCT01665092) of patients that received either L-carnitine (18g dose) or placebo using a range of pre-treatment serum acetylcarnitine and valine concentrations as measured by LC-MS or NMR, respectively"
CSV files: represent the number of at risk subjects for each representative Kaplan Meier analysis (pdf) for each acetylcarnitine (LC-MS) or valine (NMR) concentration scenario (including one for all patients) for patients that received either L-carnitine (18g) or placebo
CSV file name: SA-at risk L-carnitine 18g v PL acetylcarnitine- all pts: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo
CSV file name: SA-at risk 35然 L-carnitine 18g v PL acetylcarnitine: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo that had pre-treatment serum acetylcarnitine concentrations of 35然 or above
CSV file name: SA-at risk 30然 L-carnitine 18g v PL acetylcarnitine: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo that had pre-treatment serum acetylcarnitine concentrations of 30然 or above
CSV file name: SA-at risk 21然 L-carnitine 18g v PL acetylcarnitine: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo that had pre-treatment serum acetylcarnitine concentrations of 21然 or above
CSV file name: SA-at risk L-carnitine 18g v PL valine- all pts: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo
CSV file name: SA-at risk 88然 L-carnitine 18g v PL valine: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo that had pre-treatment serum valine concentrations of 88然 or above
CSV file name: SA-at risk 75然 L-carnitine 18g v PL valine: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo that had pre-treatment serum valine concentrations of 75然 or above
CSV file name: SA-at risk 60然 L-carnitine 18g v PL valine: represents the at risk subjects at various time points that received either L-carnitine (18g) or placebo that had pre-treatment serum valine concentrations of 60然 or above
PDF files: show the results of the survival analysis for each acetylcarnitine (LC-MS) or valine (NMR) pre-treatment concentration scenario as well as one for all patients that received either L-carnitine (18g) or placebo including the associated statistical analysis
PDF name: SA-acylcarnitines-all subjects: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo for which acylcarnitine data were obtained
PDF name: SA-acetylcarnitine-21然: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo that had pretreatment serum concentrations of 21然 or above
PDF name: SA-acetylcarnitine-30然: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo that had pretreatment serum concentrations of 30然 or above
PDF name: SA-acetylcarnitine-35uM: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo that had pretreatment serum concentrations of 35然 or above
PDF name: SA-NMR data-all subjects: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo for which NMR data were obtained
PDF name: SA-NMR data-valine-60然: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo that had pretreatment serum concentrations of 60然 or above
PDF name: SA-NMR data-valine-75然: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo that had pretreatment serum concentrations of 75然 or above
PDF name: SA-NMR data-valine-88然: shows the survival analysis results for patients that received either L-carnitine (18g) or placebo that had pretreatment serum concentrations of 88然 or above
Remediation of Harmful Language
The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to contact us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.